Ads Are Cool But Gardasil and Cervarix Vaccines Aren’t Selling

Opednews.com

December 8, 2010

Prescription drug advertising can work miracles. With Vioxx, it got 20 million people to pay five times more for a pain reliever that doubled their risk of heart attack.

But advertising may not be working with Merck’s Gardasil and GSK’s Cervarix, vaccines which protect against Human papillomavirus (HPV), the virus that causes cervical cancer.

According to research presented at the American Association for Cancer Research in Philadelphia last month, women are Just Saying No to the heavily advertised vaccine. And a third won’t return after the first inoculation, even though they are supposed to get three.

Why would women refuse a vaccine that costs $359.25 — more than any other ¬† recommended vaccine says Pew Research — but works no better than a Pap smear?

A vaccine that only works against some viral strains anyway and requires boo$ters to keep working (if it’s working) though no one even knows when?

Why would women, or their children, refuse a vaccine linked to 56 US girls’ deaths as of September according to the CDC, the death of 14-year-old Natalie Morton last year (vaccinated at her school in Coventry, UK) and suspected in the deaths of six children in trials in India last April?

PG

Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.